Barrington analyst Alexander Paris reiterated a Buy rating on Healthequity (NASDAQ: HQY) today and set a price target of $100. The company’s shares opened today at $92.89, close to its 52-week high of $97.94.
Paris observed:
“We are maintaining our OUTPERFORM investment rating and raising our 12‐month price target to $100 (from $85).”
According to TipRanks.com, Paris is a 5-star analyst with an average return of 15.5% and a 66.7% success rate. Paris covers the Services sector, focusing on stocks such as Adtalem Global Education Inc, American Public Education, and Franklin Covey Company.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Healthequity with a $96.29 average price target, a 3.7% upside from current levels. In a report released yesterday, KeyBanc also maintained a Buy rating on the stock with a $105 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $97.94 and a one-year low of $42.92. Currently, Healthequity has an average volume of 448K.
Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is negative on the stock. Most recently, in July 2018, Frank Medici, a Director at HQY sold 6,904 shares for a total of $555,013.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HealthEquity, Inc. engages in the provision of healthcare saving solutions. Its products include healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements, and healthcare incentives. The company was founded by Stephen D. Neeleman on September 18, 2002 and is headquartered in Draper, UT.
